Neurocrine Biosciences, Inc., was incorporated in California in January 1992 and re-incorporated in Delaware in May 1996. The company is a neuroscience-focused biopharmaceutical company dedicated to the discovery, development and commercialization of treatments for underaddressed neurological, psychiatric, endocrine and immune system diseases. Its product portfolio covers therapies approved by the U.S. Food and Drug Administration for the treatment of tardive dyskinesia, Huntington's disease-related chorea, classic congenital adrenal hyperplasia, endometriosis and uterine fibroids, and has a diversified pipeline of research in core therapeutic areas from small molecules to gene therapy.
